Fetoscopic Therapy for Severe Pulmonary Hypoplasia in Congenital Diaphragmatic Hernia: A First in Prenatal Regenerative Medicine at Mayo Clinic

Rodrigo Ruano, Denise B. Klinkner, Karthik Balakrishnan, Victoria A. Novoa y Novoa, Norman Davies, Dean D. Potter, William A. Carey, Christopher E. Colby, Amy B. Kolbe, Katherine W. Arendt, Leal Segura, Hans P. Sviggum, Maureen A. Lemens, Abimbola Famuyide, Andre Terzic

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: To introduce the prenatal regenerative medicine service at Mayo Clinic for fetal endoscopic tracheal occlusion (FETO) care for severe congenital diaphragmatic hernia (CDH). Patients and Methods: Two cases of prenatal management of severe CDH with FETO between January and August 2017 are reported. Per protocol, FETO was offered for life-threatening severe CDH at between 26 and 29 weeks’ gestation. Regenerative outcome end point was fetal lung growth. Gestational age at procedure and maternal and perinatal outcomes were additional monitored parameters. Results: Diagnosis by ultrasonography of severe CDH was based on extremely reduced lung size (observed-to-expected lung area to head circumference ratio [o/e-LHR], eg, o/e-LHR of 20.3% for fetus 1 and 23.0% for fetus 2) along with greater than one-third of the liver herniated into the chest in both fetuses. Both patients underwent successful FETO at 28 weeks. At the time of intervention, no maternal or fetal complications were observed. Postintervention, fetal lung growth was observed in both fetuses, reaching an o/e-LHR of 62.7% at 36 weeks in fetus 1 and 52.4% at 32 weeks in fetus 2. The balloons were removed successfully at 35 weeks and 4 days by ultrasound-guided puncture in the first patient and at 32 weeks and 3 days by ex utero intrapartum therapy-to-airway procedure in the second patient. Postnatal management followed standard of care with patch CDH therapy. At discharge, one patient was breathing normally, whereas the other required minimal nasal cannula oxygen support. Conclusion: The successful launch of the first fetoscopic therapy for CDH at Mayo Clinic reveals its feasibility and safety, with early signs of benefit documented by fetal lung growth and reversal of severe pulmonary hypoplasia. Trial Registration: clinicaltrials.gov Identifier: G170062.

Original languageEnglish (US)
Pages (from-to)693-700
Number of pages8
JournalMayo Clinic Proceedings
Volume93
Issue number6
DOIs
StatePublished - Jun 1 2018

Fingerprint

Regenerative Medicine
Fetus
Lung
Fetal Development
Therapeutics
Mothers
Case Management
Standard of Care
Punctures
Gestational Age
Congenital Diaphragmatic Hernias
Ultrasonography
Respiration
Thorax
Head
Oxygen
Safety
Pregnancy
Liver

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Fetoscopic Therapy for Severe Pulmonary Hypoplasia in Congenital Diaphragmatic Hernia : A First in Prenatal Regenerative Medicine at Mayo Clinic. / Ruano, Rodrigo; Klinkner, Denise B.; Balakrishnan, Karthik; Novoa y Novoa, Victoria A.; Davies, Norman; Potter, Dean D.; Carey, William A.; Colby, Christopher E.; Kolbe, Amy B.; Arendt, Katherine W.; Segura, Leal; Sviggum, Hans P.; Lemens, Maureen A.; Famuyide, Abimbola; Terzic, Andre.

In: Mayo Clinic Proceedings, Vol. 93, No. 6, 01.06.2018, p. 693-700.

Research output: Contribution to journalArticle

Ruano, R, Klinkner, DB, Balakrishnan, K, Novoa y Novoa, VA, Davies, N, Potter, DD, Carey, WA, Colby, CE, Kolbe, AB, Arendt, KW, Segura, L, Sviggum, HP, Lemens, MA, Famuyide, A & Terzic, A 2018, 'Fetoscopic Therapy for Severe Pulmonary Hypoplasia in Congenital Diaphragmatic Hernia: A First in Prenatal Regenerative Medicine at Mayo Clinic', Mayo Clinic Proceedings, vol. 93, no. 6, pp. 693-700. https://doi.org/10.1016/j.mayocp.2018.02.026
Ruano, Rodrigo ; Klinkner, Denise B. ; Balakrishnan, Karthik ; Novoa y Novoa, Victoria A. ; Davies, Norman ; Potter, Dean D. ; Carey, William A. ; Colby, Christopher E. ; Kolbe, Amy B. ; Arendt, Katherine W. ; Segura, Leal ; Sviggum, Hans P. ; Lemens, Maureen A. ; Famuyide, Abimbola ; Terzic, Andre. / Fetoscopic Therapy for Severe Pulmonary Hypoplasia in Congenital Diaphragmatic Hernia : A First in Prenatal Regenerative Medicine at Mayo Clinic. In: Mayo Clinic Proceedings. 2018 ; Vol. 93, No. 6. pp. 693-700.
@article{d08c1821b7bb4ab88980ead33ad8ddf3,
title = "Fetoscopic Therapy for Severe Pulmonary Hypoplasia in Congenital Diaphragmatic Hernia: A First in Prenatal Regenerative Medicine at Mayo Clinic",
abstract = "Objective: To introduce the prenatal regenerative medicine service at Mayo Clinic for fetal endoscopic tracheal occlusion (FETO) care for severe congenital diaphragmatic hernia (CDH). Patients and Methods: Two cases of prenatal management of severe CDH with FETO between January and August 2017 are reported. Per protocol, FETO was offered for life-threatening severe CDH at between 26 and 29 weeks’ gestation. Regenerative outcome end point was fetal lung growth. Gestational age at procedure and maternal and perinatal outcomes were additional monitored parameters. Results: Diagnosis by ultrasonography of severe CDH was based on extremely reduced lung size (observed-to-expected lung area to head circumference ratio [o/e-LHR], eg, o/e-LHR of 20.3{\%} for fetus 1 and 23.0{\%} for fetus 2) along with greater than one-third of the liver herniated into the chest in both fetuses. Both patients underwent successful FETO at 28 weeks. At the time of intervention, no maternal or fetal complications were observed. Postintervention, fetal lung growth was observed in both fetuses, reaching an o/e-LHR of 62.7{\%} at 36 weeks in fetus 1 and 52.4{\%} at 32 weeks in fetus 2. The balloons were removed successfully at 35 weeks and 4 days by ultrasound-guided puncture in the first patient and at 32 weeks and 3 days by ex utero intrapartum therapy-to-airway procedure in the second patient. Postnatal management followed standard of care with patch CDH therapy. At discharge, one patient was breathing normally, whereas the other required minimal nasal cannula oxygen support. Conclusion: The successful launch of the first fetoscopic therapy for CDH at Mayo Clinic reveals its feasibility and safety, with early signs of benefit documented by fetal lung growth and reversal of severe pulmonary hypoplasia. Trial Registration: clinicaltrials.gov Identifier: G170062.",
author = "Rodrigo Ruano and Klinkner, {Denise B.} and Karthik Balakrishnan and {Novoa y Novoa}, {Victoria A.} and Norman Davies and Potter, {Dean D.} and Carey, {William A.} and Colby, {Christopher E.} and Kolbe, {Amy B.} and Arendt, {Katherine W.} and Leal Segura and Sviggum, {Hans P.} and Lemens, {Maureen A.} and Abimbola Famuyide and Andre Terzic",
year = "2018",
month = "6",
day = "1",
doi = "10.1016/j.mayocp.2018.02.026",
language = "English (US)",
volume = "93",
pages = "693--700",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "6",

}

TY - JOUR

T1 - Fetoscopic Therapy for Severe Pulmonary Hypoplasia in Congenital Diaphragmatic Hernia

T2 - A First in Prenatal Regenerative Medicine at Mayo Clinic

AU - Ruano, Rodrigo

AU - Klinkner, Denise B.

AU - Balakrishnan, Karthik

AU - Novoa y Novoa, Victoria A.

AU - Davies, Norman

AU - Potter, Dean D.

AU - Carey, William A.

AU - Colby, Christopher E.

AU - Kolbe, Amy B.

AU - Arendt, Katherine W.

AU - Segura, Leal

AU - Sviggum, Hans P.

AU - Lemens, Maureen A.

AU - Famuyide, Abimbola

AU - Terzic, Andre

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Objective: To introduce the prenatal regenerative medicine service at Mayo Clinic for fetal endoscopic tracheal occlusion (FETO) care for severe congenital diaphragmatic hernia (CDH). Patients and Methods: Two cases of prenatal management of severe CDH with FETO between January and August 2017 are reported. Per protocol, FETO was offered for life-threatening severe CDH at between 26 and 29 weeks’ gestation. Regenerative outcome end point was fetal lung growth. Gestational age at procedure and maternal and perinatal outcomes were additional monitored parameters. Results: Diagnosis by ultrasonography of severe CDH was based on extremely reduced lung size (observed-to-expected lung area to head circumference ratio [o/e-LHR], eg, o/e-LHR of 20.3% for fetus 1 and 23.0% for fetus 2) along with greater than one-third of the liver herniated into the chest in both fetuses. Both patients underwent successful FETO at 28 weeks. At the time of intervention, no maternal or fetal complications were observed. Postintervention, fetal lung growth was observed in both fetuses, reaching an o/e-LHR of 62.7% at 36 weeks in fetus 1 and 52.4% at 32 weeks in fetus 2. The balloons were removed successfully at 35 weeks and 4 days by ultrasound-guided puncture in the first patient and at 32 weeks and 3 days by ex utero intrapartum therapy-to-airway procedure in the second patient. Postnatal management followed standard of care with patch CDH therapy. At discharge, one patient was breathing normally, whereas the other required minimal nasal cannula oxygen support. Conclusion: The successful launch of the first fetoscopic therapy for CDH at Mayo Clinic reveals its feasibility and safety, with early signs of benefit documented by fetal lung growth and reversal of severe pulmonary hypoplasia. Trial Registration: clinicaltrials.gov Identifier: G170062.

AB - Objective: To introduce the prenatal regenerative medicine service at Mayo Clinic for fetal endoscopic tracheal occlusion (FETO) care for severe congenital diaphragmatic hernia (CDH). Patients and Methods: Two cases of prenatal management of severe CDH with FETO between January and August 2017 are reported. Per protocol, FETO was offered for life-threatening severe CDH at between 26 and 29 weeks’ gestation. Regenerative outcome end point was fetal lung growth. Gestational age at procedure and maternal and perinatal outcomes were additional monitored parameters. Results: Diagnosis by ultrasonography of severe CDH was based on extremely reduced lung size (observed-to-expected lung area to head circumference ratio [o/e-LHR], eg, o/e-LHR of 20.3% for fetus 1 and 23.0% for fetus 2) along with greater than one-third of the liver herniated into the chest in both fetuses. Both patients underwent successful FETO at 28 weeks. At the time of intervention, no maternal or fetal complications were observed. Postintervention, fetal lung growth was observed in both fetuses, reaching an o/e-LHR of 62.7% at 36 weeks in fetus 1 and 52.4% at 32 weeks in fetus 2. The balloons were removed successfully at 35 weeks and 4 days by ultrasound-guided puncture in the first patient and at 32 weeks and 3 days by ex utero intrapartum therapy-to-airway procedure in the second patient. Postnatal management followed standard of care with patch CDH therapy. At discharge, one patient was breathing normally, whereas the other required minimal nasal cannula oxygen support. Conclusion: The successful launch of the first fetoscopic therapy for CDH at Mayo Clinic reveals its feasibility and safety, with early signs of benefit documented by fetal lung growth and reversal of severe pulmonary hypoplasia. Trial Registration: clinicaltrials.gov Identifier: G170062.

UR - http://www.scopus.com/inward/record.url?scp=85047188097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047188097&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2018.02.026

DO - 10.1016/j.mayocp.2018.02.026

M3 - Article

C2 - 29803315

AN - SCOPUS:85047188097

VL - 93

SP - 693

EP - 700

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 6

ER -